JPWO2021247924A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021247924A5 JPWO2021247924A5 JP2022574652A JP2022574652A JPWO2021247924A5 JP WO2021247924 A5 JPWO2021247924 A5 JP WO2021247924A5 JP 2022574652 A JP2022574652 A JP 2022574652A JP 2022574652 A JP2022574652 A JP 2022574652A JP WO2021247924 A5 JPWO2021247924 A5 JP WO2021247924A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- nuclease
- programmable
- casφ
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710163270 Nuclease Proteins 0.000 claims description 544
- 150000007523 nucleic acids Chemical class 0.000 claims description 421
- 102000039446 nucleic acids Human genes 0.000 claims description 350
- 108020004707 nucleic acids Proteins 0.000 claims description 350
- 238000000034 method Methods 0.000 claims description 153
- 108020005004 Guide RNA Proteins 0.000 claims description 140
- 230000000694 effects Effects 0.000 claims description 92
- 210000004027 cell Anatomy 0.000 claims description 89
- 238000003776 cleavage reaction Methods 0.000 claims description 89
- 239000000203 mixture Substances 0.000 claims description 83
- 230000007017 scission Effects 0.000 claims description 83
- 229920001184 polypeptide Polymers 0.000 claims description 81
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 81
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 81
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 78
- 108020004414 DNA Proteins 0.000 claims description 72
- 230000000295 complement effect Effects 0.000 claims description 54
- 238000012545 processing Methods 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 37
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 37
- 125000006850 spacer group Chemical group 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 102000053602 DNA Human genes 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 24
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 21
- 230000004927 fusion Effects 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 7
- 230000002103 transcriptional effect Effects 0.000 claims description 7
- 210000005260 human cell Anatomy 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000000051 modifying effect Effects 0.000 claims description 5
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims description 4
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 230000037426 transcriptional repression Effects 0.000 claims description 3
- 102000003893 Histone acetyltransferases Human genes 0.000 claims description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- 102000016397 Methyltransferase Human genes 0.000 claims description 2
- 108060004795 Methyltransferase Proteins 0.000 claims description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 2
- 102000005421 acetyltransferase Human genes 0.000 claims description 2
- 108020002494 acetyltransferase Proteins 0.000 claims description 2
- 230000006154 adenylylation Effects 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000006114 demyristoylation Effects 0.000 claims description 2
- 230000029180 desumoylation Effects 0.000 claims description 2
- 230000009504 deubiquitination Effects 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 230000007498 myristoylation Effects 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000010741 sumoylation Effects 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 claims 1
- 108091006106 transcriptional activators Proteins 0.000 claims 1
- 108091006107 transcriptional repressors Proteins 0.000 claims 1
- 238000010362 genome editing Methods 0.000 description 51
- 102000004389 Ribonucleoproteins Human genes 0.000 description 38
- 108010081734 Ribonucleoproteins Proteins 0.000 description 38
- 230000008685 targeting Effects 0.000 description 38
- 108091028113 Trans-activating crRNA Proteins 0.000 description 34
- 239000002777 nucleoside Substances 0.000 description 34
- 125000003835 nucleoside group Chemical group 0.000 description 34
- 238000003556 assay Methods 0.000 description 29
- 230000001404 mediated effect Effects 0.000 description 26
- 230000035772 mutation Effects 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 18
- 210000004962 mammalian cell Anatomy 0.000 description 18
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 15
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 15
- 238000010453 CRISPR/Cas method Methods 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 13
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 10
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 10
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 108091033409 CRISPR Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 8
- 238000012300 Sequence Analysis Methods 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 7
- 101150023212 fut8 gene Proteins 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 238000000126 in silico method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 101800005109 Triakontatetraneuropeptide Proteins 0.000 description 5
- 238000010668 complexation reaction Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000004986 primary T-cell Anatomy 0.000 description 5
- NMEHNETUFHBYEG-IHKSMFQHSA-N tttn Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 NMEHNETUFHBYEG-IHKSMFQHSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 3
- 102100026371 MHC class II transactivator Human genes 0.000 description 3
- 108700002010 MHC class II transactivator Proteins 0.000 description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 241000093740 Acidaminococcus sp. Species 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 2
- 108700004991 Cas12a Proteins 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 101150046345 Bak1 gene Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 101150024147 bax gene Proteins 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034346P | 2020-06-03 | 2020-06-03 | |
| US63/034,346 | 2020-06-03 | ||
| US202063037535P | 2020-06-10 | 2020-06-10 | |
| US63/037,535 | 2020-06-10 | ||
| US202063040998P | 2020-06-18 | 2020-06-18 | |
| US63/040,998 | 2020-06-18 | ||
| US202063092481P | 2020-10-15 | 2020-10-15 | |
| US63/092,481 | 2020-10-15 | ||
| US202063116083P | 2020-11-19 | 2020-11-19 | |
| US63/116,083 | 2020-11-19 | ||
| US202063124676P | 2020-12-11 | 2020-12-11 | |
| US63/124,676 | 2020-12-11 | ||
| US202163156883P | 2021-03-04 | 2021-03-04 | |
| US63/156,883 | 2021-03-04 | ||
| US202163178472P | 2021-04-22 | 2021-04-22 | |
| US63/178,472 | 2021-04-22 | ||
| PCT/US2021/035781 WO2021247924A1 (fr) | 2020-06-03 | 2021-06-03 | Nucléases programmables et méthodes d'utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529151A JP2023529151A (ja) | 2023-07-07 |
| JPWO2021247924A5 true JPWO2021247924A5 (fr) | 2024-06-11 |
Family
ID=78829953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574652A Withdrawn JP2023529151A (ja) | 2020-06-03 | 2021-06-03 | プログラム可能なヌクレアーゼ及び使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20230357735A1 (fr) |
| EP (1) | EP4162052A4 (fr) |
| JP (1) | JP2023529151A (fr) |
| CN (1) | CN116209755A (fr) |
| AU (1) | AU2021282578A1 (fr) |
| CA (1) | CA3178670A1 (fr) |
| WO (1) | WO2021247924A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020028729A1 (fr) | 2018-08-01 | 2020-02-06 | Mammoth Biosciences, Inc. | Compositions de nucléase programmable et leurs méthodes d'utilisation |
| AU2021368740A1 (en) * | 2020-10-30 | 2023-06-01 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting trac and uses thereof |
| WO2023173110A1 (fr) * | 2022-03-11 | 2023-09-14 | Epicrispr Biotechnologies, Inc. | Compositions, systèmes et méthodes de traitement de l'hypercholestérolémie familiale par ciblage de pcsk9 |
| WO2023220654A2 (fr) * | 2022-05-10 | 2023-11-16 | Mammoth Biosciences, Inc. | Compositions de protéines effectrices et procédés d'utilisation associés |
| WO2023220649A2 (fr) * | 2022-05-10 | 2023-11-16 | Mammoth Biosciences, Inc. | Compositions protéiques effectrices et leurs méthodes d'utilisation |
| WO2024047587A1 (fr) * | 2022-08-31 | 2024-03-07 | Regel Therapeutics, Inc. | Compositions cas-phi et méthodes d'utilisation |
| WO2024073114A1 (fr) * | 2022-09-30 | 2024-04-04 | Vedabio, Inc. | Administration d'agents thérapeutiques in vivo par l'intermédiaire d'un système en cascade basé sur crispr |
| WO2024091958A1 (fr) * | 2022-10-25 | 2024-05-02 | Mammoth Biosciences, Inc. | Protéines effectrices, compositions, systèmes et procédés de modification de serpina1 |
| WO2024107665A1 (fr) * | 2022-11-14 | 2024-05-23 | Mammoth Biosciences, Inc. | Protéines effectrices, compositions, systèmes et procédés d'utilisation associés |
| WO2024127370A1 (fr) * | 2022-12-16 | 2024-06-20 | LifeEDIT Therapeutics, Inc. | Arn guides ciblant le gène trac et procédés d'utilisation |
| WO2024137767A1 (fr) * | 2022-12-22 | 2024-06-27 | Mammoth Biosciences, Inc. | Compositions et procédés de modification de dux4 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050108791A1 (en) * | 2001-12-04 | 2005-05-19 | Edgerton Michael D. | Transgenic plants with improved phenotypes |
| US20110275135A1 (en) * | 2010-05-05 | 2011-11-10 | Battelle Energy Alliance, Llc | Genetic elements, proteins, and associated methods including application of additional genetic information to gram (+) thermoacidophiles |
| US20140113376A1 (en) * | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
| EP3800248A3 (fr) * | 2014-04-18 | 2021-08-04 | Editas Medicine, Inc. | Méthodes, compositions et constituants associés à crispr/cas pour l'immunothérapie du cancer |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP3445853A1 (fr) * | 2016-04-19 | 2019-02-27 | The Broad Institute, Inc. | Complexes cpf1 à activité d'indel réduite |
| WO2020181101A1 (fr) * | 2019-03-07 | 2020-09-10 | The Regents Of The University Of California | Polypeptides effecteurs crispr-cas et procédés d'utilisation associés |
-
2021
- 2021-06-03 JP JP2022574652A patent/JP2023529151A/ja not_active Withdrawn
- 2021-06-03 CA CA3178670A patent/CA3178670A1/fr active Pending
- 2021-06-03 WO PCT/US2021/035781 patent/WO2021247924A1/fr unknown
- 2021-06-03 CN CN202180056722.7A patent/CN116209755A/zh active Pending
- 2021-06-03 EP EP21819013.0A patent/EP4162052A4/fr active Pending
- 2021-06-03 AU AU2021282578A patent/AU2021282578A1/en active Pending
- 2021-06-03 US US18/000,640 patent/US20230357735A1/en active Pending
-
2022
- 2022-08-11 US US17/819,137 patent/US20230167454A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tao et al. | Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing | |
| US20210324382A1 (en) | Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing | |
| JP7067793B2 (ja) | 核酸塩基編集因子およびその使用 | |
| Anderson et al. | Systematic analysis of CRISPR–Cas9 mismatch tolerance reveals low levels of off-target activity | |
| Nazarkina et al. | XRCC1 interactions with base excision repair DNA intermediates | |
| Smith et al. | Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. | |
| CA3106035A1 (fr) | Enzymes cas12b et systemes | |
| JP2017537618A (ja) | 標的化ｒｎａ編集 | |
| Wilkinson et al. | CRISPR RNA-guided autonomous delivery of Cas9 | |
| JP2016534116A (ja) | 操作された転写活性化因子様エフェクター（ｔａｌｅ）ドメインおよびその使用 | |
| NZ716832A (en) | Nuclease profiling system | |
| US9238814B2 (en) | Ribozyme for identifying modification on RNA sequence and RNA cleavage method using same | |
| CN111989113B (zh) | 用于治疗癌症的包含向导rna和核酸内切酶作活性成分的药物组合物 | |
| Sledzinski et al. | Paving the way towards precise and safe CRISPR genome editing | |
| WO2020206036A1 (fr) | Nouveau modificateur d'acide nucléique | |
| JPWO2021247924A5 (fr) | ||
| CN110248957A (zh) | 经人工操纵的sc功能控制系统 | |
| KR20240023081A (ko) | CRISPR/Cas12f1(Cas14a1) system 효율화를 위한 engineered guide RNA 및 이의 용도 | |
| US20210340568A1 (en) | Regulated gene editing system | |
| CN114144519A (zh) | 单碱基置换蛋白以及包含其的组合物 | |
| Bestas et al. | A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo | |
| Kondrateva et al. | An overview of currently available molecular Cas-tools for precise genome modification | |
| KR102638799B1 (ko) | CRISPR/Cas12f1(Cas14a1) system 효율화를 위한 engineered guide RNA 및 이의 용도 | |
| JP5990171B2 (ja) | Ｈｓｐｃ１１７分子のｒｎａリガーゼとしての使用 | |
| JP2024518793A (ja) | 向上した安定性を有するｃａｓ９エフェクタータンパク質 |